Defining the optimal lymphadenectomy cut-off value in epithelial ovarian cancer staging surgery utilizing a mathematical model of validation

2013 ◽  
Vol 39 (3) ◽  
pp. 290-296 ◽  
Author(s):  
A. Pereira ◽  
N. Irishina ◽  
T. Pérez-Medina ◽  
J.F. Magrina ◽  
P.M. Magtibay ◽  
...  
Keyword(s):  
Mathematical Model ◽  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Staging ◽  
Staging Surgery

scholarly journals Development and validation of a nomogram to predict survival outcome among epithelial ovarian cancer patients with site-distant metastases: a population-based study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Bo Wang ◽  
Shixuan Wang ◽  
Wu Ren
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Bone Metastasis ◽  
Epithelial Ovarian Cancer ◽  
Lung Metastasis ◽  
Lymphatic Metastasis ◽  
Staging System ◽  
Distant Metastases ◽  
Figo Staging ◽  
Staging Surgery

Abstract Background Increasing evidence indicates that site-distant metastases are associated with survival outcomes in patients with epithelial ovarian cancer. This study aimed to investigate the prognostic values of site-distant metastases and clinical factors and develop a prognostic nomogram score individually predicting overall survival (OS, equivalent to all-cause mortality) and cancer specific survival (CSS, equivalent to cancer-specific mortality) in patients with epithelial ovarian cancer. Methods We retrospectively collected data on patients with epithelial ovarian cancer from the Surveillance, Epidemiology, and End Results (SEER) database between 1975 and 2016. Multivariate Cox regression was performed to identify survival trajectories. A nomogram score was used to predict long-term survival probability. A comparison between the nomogram and the International Federation of Gynecology and Obstetrics (FIGO 2018) staging system was conducted using time-dependent receiver operating characteristic (tROC) curve. Results A total of 131,050 patients were included, 18.2, 7.8 and 66.1% had localized, regional and distant metastases, respectively. Multivariate analysis identified several prognostic factors for OS including race, grade, histology, FIGO staging, surgery, bone metastasis, liver metastasis, lung metastasis, and lymphatic metastasis. Prognostic factors for CSS included grade, site, FIGO staging, surgery, bone metastasis, brain metastasis, lung metastasis, lymphatic metastasis, and insurance. Following bootstrap correction, the C-index of OS and CSS was 0.791 and 0.752, respectively. These nomograms showed superior performance compared with the FIGO 2018 staging criteria (P < 0.05). Conclusions A novel prognostic nomogram score provides better prognostic performance than the FIGO 2018 staging system. These nomograms contribute to directing clinical treatment and prognosis assessment in patients harboring site-distant metastases.

scholarly journals Modelling the Effects of Paclitaxel and Cisplatin on Breast and Ovarian Cancer

2000 ◽  
Vol 3 (1) ◽  
pp. 11-23
Author(s):  
John Carl Panetta ◽  
Mark A. J. Chaplain ◽  
David Cameron
Keyword(s):  
Mathematical Model ◽  
Cell Cycle ◽  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Studies ◽  
First Line ◽  
Breast And Ovarian Cancer ◽  
Cytotoxic Effects ◽  
Treatment Regimens ◽  
Line Chemotherapy

The two drugs, Paclitaxel and Cisplatin, have important roles in the treatment of breast and ovarian cancer, with the combination currently considered the optimum first line chemotherapy of epithelial ovarian cancer. There has been a variety of experimental and clinical studies to try to determine the most effective method to deliver these drugs. These studies consistently show that giving Paclitaxel prior to Cisplatin is the more effective regimen. However, the reasons why are not fully understood. Therefore, we have developed a mathematical model to describe and predict the effects of these two drugs. This model takes into account the cytotoxic effects of the drugs on the cell-cycle and the pharmacodynamic and pharmacokinetic effects of the drugs on each other. The model agrees with the experimental and clinical studies which show that Paclitaxel given prior to Cisplatin is the better combination and, in addition, the model also predicts more effective treatment regimens. These include conditions on the time between doses and the dosing of each of the drugs.

scholarly journals A cross-sectional study: The correlation of pro-angiogenic factors expression level and epithelial ovarian cancer staging

2020 ◽  
Vol 9 (1) ◽  
pp. 125
Author(s):  
Teguh Prakosa ◽  
Ambar Mudigdo ◽  
Bambang Purwanto ◽  
Brian Wasita ◽  
Risya Cilmiaty ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Staging ◽  
Cross Sectional Study ◽  
Angiogenic Factors ◽  
Expression Level ◽  
Sectional Study ◽  
Cross Sectional

Impact of extended cycles of chemotherapy on survival outcome in recurrent epithelial ovarian cancer

2020 ◽  
Vol 159 ◽  
pp. 346-347
Author(s):  
W.Y. Hwang ◽  
S.I. Kim ◽  
M. Lee ◽  
K. Kim ◽  
J.H. No ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Survival Outcome

Die personalisierte Therapie beim Ovarialkarzinom

2018 ◽  
Vol 39 (03) ◽  
pp. 180-186
Author(s):  
Ann-K. Langner ◽  
Nina Pauly ◽  
Beyhan Ataseven ◽  
Andreas du Bois
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Personalisierte Medizin ◽  
Personalisierte Therapie

Die Behandlung des epithelialen Ovarial-, Tuben- und Peritonealkarzinoms (epithelial ovarian cancer; EOC) fußt auf 3 Säulen, die in unterschiedlichem Maße individualisierte bzw. personalisierte Medizin inkludieren:

Sign in / Sign up

Export Citation Format

Share Document